These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacokinetics of buprenorphine: a comparison of sublingual tablet versus liquid after chronic dosing. Compton P; Ling W; Chiang CN; Moody DE; Huber A; Ling D; Charuvastra C J Addict Med; 2007 Jun; 1(2):88-95. PubMed ID: 21768940 [TBL] [Abstract][Full Text] [Related]
5. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D; N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743 [TBL] [Abstract][Full Text] [Related]
6. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects. Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912 [TBL] [Abstract][Full Text] [Related]
7. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects. Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728 [TBL] [Abstract][Full Text] [Related]
8. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial. Gunderson EW; Hjelmström P; Sumner M; Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801 [TBL] [Abstract][Full Text] [Related]
9. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Strain EC; Moody DE; Stoller KB; Walsh SL; Bigelow GE Drug Alcohol Depend; 2004 Apr; 74(1):37-43. PubMed ID: 15072805 [TBL] [Abstract][Full Text] [Related]
14. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. McCance-Katz EF; Moody DE; Smith PF; Morse GD; Friedland G; Pade P; Baker J; Alvanzo A; Jatlow P; Rainey PM Clin Infect Dis; 2006 Dec; 43 Suppl 4():S235-46. PubMed ID: 17109310 [TBL] [Abstract][Full Text] [Related]
15. Early experience with Suboxone maintenance therapy in Hungary. Demetrovics Z; Farkas J; Csorba J; Németh A; Mervó B; Szemelyácz J; Fleischmann E; Kassai-Farkas A; Petke Z; Oroján T; Rózsa S; Rigó P; Funk S; Kapitány M; Kollár A; Rácz J Neuropsychopharmacol Hung; 2009 Dec; 11(4):249-57. PubMed ID: 20150662 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial. Webster L; Hjelmström P; Sumner M; Gunderson EW J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785 [TBL] [Abstract][Full Text] [Related]
17. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. Mintzer MZ; Correia CJ; Strain EC Drug Alcohol Depend; 2004 May; 74(2):205-9. PubMed ID: 15099664 [TBL] [Abstract][Full Text] [Related]
18. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects. Henney HR; Shah J Clin Ther; 2007 Apr; 29(4):661-9. PubMed ID: 17617289 [TBL] [Abstract][Full Text] [Related]
19. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection. Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. Harris DS; Mendelson JE; Lin ET; Upton RA; Jones RT Clin Pharmacokinet; 2004; 43(5):329-40. PubMed ID: 15080765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]